Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy.

ABSTRACT: Diabetic nephropathy is a growing global health challenge, significantly increasing the risks of hypertension and cardiovascular complications. Despite existing treatment options, none effectively promote renal repair or halt disease progression. We aimed to investigate the role of O-GlcNAc modification and the potential of Metformin as a therapeutic agent in diabetic nephropathy. In this study, we recruited diabetic nephropathy patients and treated them with Metformin. In addition, this research employed pharmacological and genetic methods to examine the impact of O-GlcNAc modification on diabetic nephropathy rat models and mesangial cells. Significant improvements in kidney function were observed in diabetic nephropathy patients treated with Metformin, as evidenced by reduced serum bioma

SUBMITTER: Qi B 

PROVIDER: S-EPMC12719668 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature